https://orcid.org/0000-0003-2523-050X
Citations (35)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Fabrizio Martora, Teresa Battista, Luca Potestio, Antonio Portarapillo, Nello Tommasino & Matteo Megna. (2024) Long-Term Efficacy of Guselkumab in an Adolescent Hidradenitis Suppurativa Patients: A Case Report. Clinical, Cosmetic and Investigational Dermatology 17, pages 483-487.
Read now
Read now
Luca Potestio, Fabrizio Martora, Gabriella Fabbrocini, Teresa Battista & Matteo Megna. (2023) Safety and Efficacy of Covid-19 Vaccination in Patients Undergoing Biological Treatments for Psoriasis. Psoriasis: Targets and Therapy 13, pages 11-18.
Read now
Read now
Luca Potestio, Matteo Megna, Alessia Villani, Sara Cacciapuoti, Massimiliano Scalvenzi & Fabrizio Martora. (2023) Herpes Zoster and COVID-19 Vaccination: A Narrative Review. Clinical, Cosmetic and Investigational Dermatology 16, pages 3323-3331.
Read now
Read now
Fabrizio Martora, Massimiliano Scalvenzi, Teresa Battista, Luigi Fornaro, Luca Potestio, Angelo Ruggiero & Matteo Megna. (2023) Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data. Clinical, Cosmetic and Investigational Dermatology 16, pages 2525-2536.
Read now
Read now
Teresa Battista, Massimiliano Scalvenzi, Fabrizio Martora, Luca Potestio & Matteo Megna. (2023) Nail Psoriasis: An Updated Review of Currently Available Systemic Treatments. Clinical, Cosmetic and Investigational Dermatology 16, pages 1899-1932.
Read now
Read now
Luca Potestio, Elisa Camela, Sara Cacciapuoti, Luigi Fornaro, Angelo Ruggiero, Fabrizio Martora, Teresa Battista & Matteo Megna. (2023) Biologics for the Management of Erythrodermic Psoriasis: An Updated Review. Clinical, Cosmetic and Investigational Dermatology 16, pages 2045-2059.
Read now
Read now
D. Willems, C. J. Sayed, H. H. Van der Zee, J. R. Ingram, E.-L. Hinzpeter, C. Beaudart, S. M. A. A. Evers & M. Hiligsmann. (2023) A discrete-choice experiment to elicit the treatment preferences of patients with hidradenitis suppurativa in the United States. Journal of Medical Economics 26:1, pages 503-508.
Read now
Read now
Ceylan Avcı, Gülfem Akın, Sevgi Akarsu & Banu Lebe. (2023) Pyoderma gangrenosum and Behçet’s-like disease induced by secukinumab: a paradoxical drug reaction. Journal of Dermatological Treatment 34:1.
Read now
Read now
Carlo Alberto Maronese, Chiara Moltrasio, Giovanni Genovese & Angelo Valerio Marzano. (2023) Biologics for Hidradenitis suppurativa: evolution of the treatment paradigm. Expert Review of Clinical Immunology 0:0, pages 1-21.
Read now
Read now
Corey L Snyder, Ruby S Gibson, Martina L Porter & Alexa B Kimball. (2023) Secukinumab in the Treatment of Hidradenitis Suppurativa. Immunotherapy 15:17, pages 1449-1457.
Read now
Read now
Luca Potestio, Elisa Camela, Sara Cacciapuoti, Fabrizio Martora, Luigi Guerriero, Luigi Fornaro, Angelo Ruggiero & Matteo Megna. (2023) Efficacy and safety of spesolimab for the management of generalized pustular psoriasis: a drug safety evaluation. Expert Opinion on Drug Safety 22:11, pages 1003-1010.
Read now
Read now
Yixiao Liu, Ling Xu, Xinrui Wang, Lijuan Wu, Ruifen Cai, Lujin Li & Qingshan Zheng. (2023) Optimization of secukinumab dose regimens in patients with moderate-to-severe plaque psoriasis via exposure-response modeling. Expert Review of Clinical Pharmacology 16:10, pages 999-1008.
Read now
Read now
Articles from other publishers (23)
Teresa Battista, Lucia Gallo, Fabrizio Martora, Davide Fattore, Luca Potestio, Sara Cacciapuoti, Massimiliano Scalvenzi & Matteo Megna. (2024) Biological Therapy for Psoriasis in Cancer Patients: An 8-Year Retrospective Real-Life Study. Journal of Clinical Medicine 13:7, pages 1940.
Crossref
Crossref
Natale Schettini, Elisa Marzola, Lucrezia Pacetti, Simone Cavaliere & Vincenzo Bettoli. (2024) A Case of Dissecting Cellulitis of the Scalp, Hidradenitis Suppurativa, and Conglobate Acne Successfully Treated with Secukinumab. Skin Appendage Disorders, pages 1-4.
Crossref
Crossref
Jessica R. Allegretti, Jessica H. Brady, Ann Wicker, Mark Latymer & Alvin Wells. (2024) Relevance of Adalimumab Product Attributes to Patient Experience in the Biosimilar Era: A Narrative Review. Advances in Therapy.
Crossref
Crossref
Fabrizio Martora, Luca Potestio, Teresa Battista & Matteo Megna. (2024) Reply to “Improved clinical effectiveness of adalimumab when initiated with clindamycin and rifampicin in hidradenitis suppurativa”. Journal of the European Academy of Dermatology and Venereology.
Crossref
Crossref
Rene Chen, Robyn Guo, Amy J. Petty & Tarannum Jaleel. (2024) Immune Dysregulation and Current Targeted Biologics in Hidradenitis Suppurativa. Immuno 4:1, pages 57-76.
Crossref
Crossref
Yi-Lun Chu & Sebastian Yu. (2024) Hidradenitis Suppurativa: An Understanding of Genetic Factors and Treatment. Biomedicines 12:2, pages 338.
Crossref
Crossref
Jonathan Kay, Raymond K. Cross, Steven R. Feldman, Younjin Park & Stephen B. Hanauer. (2023) Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases. Advances in Therapy 41:2, pages 509-533.
Crossref
Crossref
Anna Wolinska, Paula Beatty, Marta Costa Blasco, Orla McFeely, Lisa Murphy, Madonna Andrawis, Claire Doyle & Anne-Marie Tobin. (2024) The impact of early-onset hidradenitis suppurativa. Clinical and Experimental Dermatology.
Crossref
Crossref
Francisca Martins, Alexandra Rodrigues, João Fonseca Oliveira, Rui Malheiro & Luís Cerqueira. (2024) Cerebral Tuberculosis After Therapy With Adalimumab for Hidradenitis Suppurativa: A Rare Case. Cureus.
Crossref
Crossref
Gyula László Fekete, László Fekete, László Barna Iantovics, Júlia E. Fekete & Ilarie Brihan. (2024) Multiple verrucous squamous cell carcinomas developing on chronic hidradenitis suppurativa lesions—a rare case report from Romania. Frontiers in Medicine 11.
Crossref
Crossref
Hannah Gier, Alexa Israeli, Austin Cusick & Dawn Merritt. (2023) Use of Interleukin-12/23 Inhibitor for the Management of Acne Fulminans. Cureus.
Crossref
Crossref
Fabrizio Martora, Angelo Ruggiero, Luca Potestio, Teresa Battista & Matteo Megna. (2023) Reply to “Dalbavancin for the treatment of severe hidradenitis suppurativa”. Journal of the European Academy of Dermatology and Venereology 37:11.
Crossref
Crossref
Nicholas Chiang, Cathryn Sibbald, Rebecca Levy & Irene Lara-Corrales. (2023) Hidradenitis Suppurativa in Children and Adolescents: An Update on Pharmacologic Treatment Options. Pediatric Drugs 25:6, pages 659-676.
Crossref
Crossref
Luigi FORNARO, Dario MARASCA, Gabriella FABBROCINI, Matteo MEGNA, Fabrizio MARTORA & Claudio MARASCA. (2023) Tattooing and hidradenitis suppurativa: stigmatization and camouflage. Italian Journal of Dermatology and Venereology 158:5.
Crossref
Crossref
Max Gabutti, Kristine Heidemeyer, S. Morteza Seyed Jafari, Simon Bossart, Robert E. Hunger, Laurence Feldmeyer & Nikhil Yawalkar. (2023) Dimethyl Fumarate Used as an Effective Treatment for Granuloma Annulare Disseminatum: An Immunohistochemical Case Study. International Journal of Molecular Sciences 24:17, pages 13355.
Crossref
Crossref
Dillon Mintoff, Rachel Agius, Stephen Fava & Nikolai P. Pace. (2023) Investigating Adiposity-Related Metabolic Health Phenotypes in Patients with Hidradenitis Suppurativa: A Cross-Sectional Study. Journal of Clinical Medicine 12:14, pages 4847.
Crossref
Crossref
Fabrizio Martora, Angelo Ruggiero, Teresa Battista, Luca Potestio & Matteo Megna. (2023) Comment on ‘Associations between hidradenitis suppurativa and dermatological conditions in adults: a national cross-sectional study’. Clinical and Experimental Dermatology 48:8, pages 938-939.
Crossref
Crossref
Fabrizio Martora, Teresa Battista, Luca Potestio, Massimiliano Scalvenzi, Paola Nappa & Matteo Megna. (2023) Comment on ‘Onset of epidermolysis bullosa acquisita under therapy with ustekinumab for the treatment of Crohn disease’. Clinical and Experimental Dermatology 48:8, pages 930-931.
Crossref
Crossref
Fabrizio Martora, Teresa Battista, Angelo Ruggiero, Massimiliano Scalvenzi, Alessia Villani, Matteo Megna & Luca Potestio. (2023) The Impact of COVID-19 Vaccination on Inflammatory Skin Disorders and Other Cutaneous Diseases: A Review of the Published Literature. Viruses 15:7, pages 1423.
Crossref
Crossref
Fabrizio Martora, Gabriella Fabbrocini, Claudio Marasca, Teresa Battista & Matteo Megna. (2023) Paradoxical hidradenitis suppurativa induced by adalimumab biosimilar successfully treated with guselkumab in a patient with psoriasis. Comment on ‘Paradoxical hidradenitis suppurativa due to anti-interleukin-1 agents for mevalonate kinase deficiency successfully treated with the addition of ustekinumab’. Clinical and Experimental Dermatology 48:6, pages 701-703.
Crossref
Crossref
Fabrizio Martora, Massimiliano Scalvenzi, Angelo Ruggiero, Luca Potestio, Teresa Battista & Matteo Megna. (2023) Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature. Medicina 59:4, pages 801.
Crossref
Crossref
Fabrizio Martora, Gabriella Fabbrocini, Matteo Megna, Massimiliano Scalvenzi, Teresa Battista, Alessia Villani & Luca Potestio. (2023) Teledermatology for Common Inflammatory Skin Conditions: The Medicine of the Future?. Life 13:4, pages 1037.
Crossref
Crossref
Aikaterini Tsiogka, Aikaterini I. Liakou, Efthimia Agiasofitou, Stamatis Gregoriou, Alexander Stratigos, Dimitrios Rigopoulos & Georgios Kontochristopoulos. (2023) Adalimumab-Induced Paradoxical Psoriasis Treated with Biologics Targeting the IL-17/IL-23 Axis in Patients with Hidradenitis Suppurativa. Dermatology 239:6, pages 937-941.
Crossref
Crossref